Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Gilead Sciences, Inc. < Previous 1 2 3 4 5 6 7 8 Next > Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies January 03, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics December 27, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD JNCE Gilead Sciences to Present at Upcoming Investor Conference December 23, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma December 22, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV December 22, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer December 20, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Again Named to Dow Jones Sustainability World Index December 12, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response December 12, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months December 12, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma December 11, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis December 11, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma December 09, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers ACLX GILD Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan December 07, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer December 06, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations November 29, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Present at Upcoming Investor Conferences November 15, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022 November 03, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients November 02, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease November 01, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces Third Quarter 2022 Financial Results October 27, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities October 24, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers October 20, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022 October 18, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma October 17, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies October 17, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD MGNX Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022 October 13, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer October 11, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product October 03, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines September 22, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Completes Acquisition of MiroBio September 20, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.